Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s always a great day when a company finds a new way to treat an illness, especially when that illness is quite rare. ChemoCentryx (NASDAQ: CCXI ) holders are having a better day than most, with their po...
Gainers: ChemoCentryx CCXI +57%, ReShape Lifesciences (NASDAQ:RSLS) +30%, Voyager Therapeutics VYGR +13%, Sundial Growers (NASDAQ:SNDL) +10%, Flora Growth (NASDAQ:FLGC) +6%. Losers: Allogene Therapeutics ALLO -42%, Cellectis CLLS -19%,...
ChemoCentryx Inc ( NASDAQ: CCXI ) shareholders had every reason to be happy about on Friday morning. The shares of the group traded higher on Friday morning, thanks to the announcement made by the group. The company announced that it had received the U.S. Food and Drug Adminis...
After ChemoCentryx (NASDAQ:CCXI) announced that its ANCA vasculitis candidate TAVNEOS (avacopan) won the FDA approval, InflaRx (NASDAQ:IFRX), a rival developer for the indication, is also trading higher in solidarity. While ChemoCentryx (CCXI) has jumped ~84.4% in the pre-market wit...
-- First FDA-approved orally-administered inhibitor of the complement 5a receptor -- -- Company to hold conference call at 8:30 a.m. Eastern Time -- SAN CARLOS, Calif., Oct. 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food...
Gainers: GDS +9.2%. APP +9.1%. TWOU +8.7%. RGP +7.7%. CCXI +3.7%. Losers: OSMT -22.2%. STSA -6.4%. VYGR -5.2%. CMPI -4.4%. AVT -4.2%. For further details see: GDS, APP, OSMT and STSA among after hours movers
ChemoCentryx is developing Avacopan - a C5 complement receptor inhibitor - for several autoimmune conditions. The company has an upcoming PDUFA date for Avacopan in ANCA vasculitis - the FDA will make its decision on whether to approve the drug on October 7th. The original date wa...
SAN CARLOS, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Kissei Pharmaceutical Co., Ltd. has received approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW) to market TAVNEOS™ (avacopan), an orally administ...
The S&P 500 has been showing signs of weakness to start September, down by more than 1% so far this month. And with many stocks in the index trading at highs, there's definitely room for more of a correction to take place. Given that the index has soared more than 50% since March 20...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...